LearnGlossaryMarketStocksSuperinvestorsSign in

GKOS

Glaukos Corporation

Healthcare · $9.1B market cap

Verdict

We can't put a fair value on GKOS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth51.8% a year✓
Equity per share growth13.9% a year✓
Sales growth18.2% a year✓
Free cash flow growth—?
Return on invested capital-13.0%✗

Follow GKOS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds GKOS. In Q2 2026, 1 opened a position. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$673K

4,818 shares

Moves in Q2 2026

New position: Polen Capital Management

About Glaukos Corporation

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works